David Tobias Martin, M.B.,B.S., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Defibrillators, Implantable | 12 | 2024 | 1498 | 1.380 |
Why?
|
| Cardiac Resynchronization Therapy | 5 | 2024 | 560 | 0.680 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2015 | 122 | 0.450 |
Why?
|
| Pacemaker, Artificial | 3 | 2024 | 828 | 0.390 |
Why?
|
| Atrial Fibrillation | 6 | 2023 | 5176 | 0.340 |
Why?
|
| Equipment Failure | 2 | 2018 | 585 | 0.330 |
Why?
|
| Arrhythmias, Cardiac | 5 | 2023 | 2258 | 0.330 |
Why?
|
| Heart Block | 1 | 2011 | 390 | 0.320 |
Why?
|
| Anticoagulants | 4 | 2023 | 4852 | 0.250 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 1737 | 0.250 |
Why?
|
| Ventricular Dysfunction | 1 | 2005 | 144 | 0.230 |
Why?
|
| Device Removal | 2 | 2021 | 643 | 0.230 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2024 | 1415 | 0.230 |
Why?
|
| Tachycardia, Ventricular | 2 | 2023 | 1309 | 0.230 |
Why?
|
| Thromboembolism | 2 | 2022 | 1004 | 0.200 |
Why?
|
| Diabetes Mellitus | 2 | 2011 | 5889 | 0.190 |
Why?
|
| Myocardial Revascularization | 1 | 2005 | 795 | 0.190 |
Why?
|
| Heart Injuries | 1 | 2023 | 207 | 0.190 |
Why?
|
| Heart Failure | 4 | 2023 | 11879 | 0.180 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2024 | 362 | 0.170 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2021 | 1567 | 0.150 |
Why?
|
| Electric Countershock | 1 | 2021 | 534 | 0.150 |
Why?
|
| Cardiovascular Agents | 1 | 2022 | 849 | 0.130 |
Why?
|
| Catheterization, Peripheral | 1 | 2018 | 347 | 0.110 |
Why?
|
| Wireless Technology | 1 | 2015 | 102 | 0.110 |
Why?
|
| Patient Selection | 1 | 2005 | 4260 | 0.110 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2024 | 881 | 0.100 |
Why?
|
| Stroke | 4 | 2022 | 9755 | 0.100 |
Why?
|
| Monitoring, Ambulatory | 1 | 2015 | 358 | 0.100 |
Why?
|
| Single-Blind Method | 1 | 2015 | 1587 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 11519 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2018 | 2028 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2023 | 3683 | 0.070 |
Why?
|
| Atrial Flutter | 1 | 2009 | 253 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2018 | 3048 | 0.070 |
Why?
|
| Ventricular Function, Left | 3 | 2023 | 3941 | 0.060 |
Why?
|
| Risk Factors | 7 | 2024 | 74944 | 0.060 |
Why?
|
| Heart Rate | 2 | 2021 | 4214 | 0.060 |
Why?
|
| Aged | 10 | 2023 | 171504 | 0.050 |
Why?
|
| Treatment Outcome | 6 | 2023 | 65371 | 0.050 |
Why?
|
| Stroke Volume | 3 | 2023 | 5622 | 0.050 |
Why?
|
| Humans | 19 | 2024 | 768166 | 0.050 |
Why?
|
| Defibrillators | 1 | 2022 | 39 | 0.050 |
Why?
|
| Apnea | 1 | 2023 | 195 | 0.050 |
Why?
|
| Registries | 1 | 2018 | 8375 | 0.050 |
Why?
|
| Exercise Test | 1 | 2009 | 2186 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2009 | 6229 | 0.050 |
Why?
|
| Ritonavir | 1 | 2022 | 331 | 0.040 |
Why?
|
| Risk Assessment | 3 | 2021 | 24315 | 0.040 |
Why?
|
| Ventricular Fibrillation | 1 | 2023 | 537 | 0.040 |
Why?
|
| Middle Aged | 8 | 2023 | 223492 | 0.040 |
Why?
|
| Male | 10 | 2023 | 364719 | 0.040 |
Why?
|
| Pericardium | 1 | 2023 | 679 | 0.040 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2009 | 2145 | 0.040 |
Why?
|
| Female | 10 | 2023 | 397192 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2022 | 1419 | 0.040 |
Why?
|
| Telemedicine | 1 | 2015 | 3109 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2005 | 1043 | 0.040 |
Why?
|
| Survival Rate | 2 | 2023 | 12840 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 12543 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2009 | 6412 | 0.030 |
Why?
|
| Heart Atria | 1 | 2022 | 1361 | 0.030 |
Why?
|
| Hemorrhage | 2 | 2023 | 3467 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13676 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2018 | 15832 | 0.030 |
Why?
|
| Veins | 1 | 2018 | 769 | 0.030 |
Why?
|
| Action Potentials | 1 | 2021 | 1838 | 0.030 |
Why?
|
| Cause of Death | 1 | 2023 | 3721 | 0.030 |
Why?
|
| Adenine | 1 | 2018 | 995 | 0.030 |
Why?
|
| Prevalence | 1 | 2009 | 15869 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 2018 | 945 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2009 | 22291 | 0.020 |
Why?
|
| Incidence | 2 | 2021 | 21538 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2016 | 1162 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2009 | 41754 | 0.020 |
Why?
|
| Piperidines | 1 | 2018 | 1667 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2016 | 4030 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2023 | 54926 | 0.020 |
Why?
|
| Telemetry | 1 | 2009 | 200 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 26379 | 0.020 |
Why?
|
| Embolism | 1 | 2009 | 401 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2023 | 59629 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2018 | 2819 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 10760 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2018 | 5349 | 0.010 |
Why?
|
| Prognosis | 1 | 2024 | 30010 | 0.010 |
Why?
|
| Pandemics | 1 | 2022 | 8748 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 39348 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 6211 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 60066 | 0.010 |
Why?
|
| United States | 1 | 2018 | 73039 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2018 | 81762 | 0.000 |
Why?
|
| Adult | 1 | 2018 | 223646 | 0.000 |
Why?
|